TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Docetaxel
PubChem CID 148124
Molecular Weight 807.9g/mol
Synonyms

docetaxel, 114977-28-5, Taxotere, Docetaxel anhydrous, Docetaxel Winthrop, Docetaxol, Docetaxel Kabi, EmDOC, Docetaxolum, Docefrez, Taxoel, Docetaxel Teva, Docetaxel Accord, RP-56976, Docetaxel [INN], Docetaxel, anhydrous, DOCETAXEL MYLAN, Docecad, NSC-628503, DTXSID0040464, N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol, RP 56976, TXL, DOCETAXEL TEVA PHARMA, NSC 628503, UNII-699121PHCA, CHEBI:4672, HSDB 6965, N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol, 699121PHCA, Taxotere (TN), RP56976, CABAZITAXEL METABOLITE (RP56976), BIND 014, N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel, DTXCID8020464, CKD-810, NSC628503, [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate, Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, Docetaxel, Trihydrate, taxotel, DOCETAXEL (USP-RS), UNII-15H5577CQD, MFCD00800737, Docetaxel (Taxotere), DOCETAXEL (EP MONOGRAPH), DOCETAXEL (USP IMPURITY), DOCETAXEL (USP MONOGRAPH), (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate, (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate, 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate, Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-, CAS-114977-28-5, NSC 759850, Docetaxolum [INN-Latin], DOCETAXEL TRIHYDRATE (EP MONOGRAPH), docetaxelum, MFCD00871399, docetaxel 114977-28-5, XRP-6976L, ANX-514, SDP-014, SID 530, Docetaxel (TN), Docetaxel- Bio-X, NCGC00181306-01, NCGC00181306-02, 4-(acetyloxy)-13alpha-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate, Taxotere (Aventis), CID148124, Docetaxolum (Latin), N-debenzoyl-N-Boc-10-deacetyl taxol, bind-014, Docetaxel (JAN/INN), DOCETAXEL [JAN], DOCETAXEL [MI], CHEMBL92, DOCETAXEL [HSDB], Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,1313-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, trihydrate, (alphaR,betaS)-, SCHEMBL4419, N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol, GTPL6809, BIND 014 [WHO-DD], BDBM36351, SYP-0704A, ZDZOTLJHXYCWBA-VCVYQWHSSA-, AMY4356, L01CD02, 114977-28-5, Docetaxel, HMS2089K08, 114915-20-7, EX-A1206, HY-B0011, Tox21_112781, Tox21_113088, AC-383, DOCETAXEL ANHYDROUS [WHO-DD], AKOS015960718, AKOS024457953, Tox21_112781_1, CS-1144, DB01248, KS-1452, Docetaxel, purum, >=97.0% (HPLC), NCGC00181306-04, NCGC00242509-01, BD164373, D4102, FT-0625558, NS00006849, D07866, EN300-123047, AB01273941-01, AB01273941-02, Q420436, SR-01000003023, W-60384, Q-100074, SR-01000003023-5, BRD-K30577245-001-04-3, BRD-K30577245-341-01-9, Z1546621742, Anhydrous Docetaxel, European Pharmacopoeia (EP) Reference Standard, (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,7,10-trihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-(1,1-dimethylethyl)oxycarbonylamino-2-hydroxy-3-phenylpropanoate, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate, (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate, (2R,3S)-N-CARBOXY-3-PHENYLISOSERINE, N-TERT-BUTYL ESTER, 13-ESTER WITH 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA.,10.BETA.,13.ALPHA.-HEXAHYDROXYTAX-11-EN-9-ONE 4-ACETATE 2-BENZOATE, (2R,3S)-N-CARBOXY-3-PHENYLISOSERINE, N-TERT-BUTYL ESTER, 13-ESTER WITH 5beta,20-EPOXY-1,2alpha,4,7beta,10beta,13alpha-HEXAHYDROXYTAX-11-EN-9-ONE 4-ACETATE 2-BENZOATE, [acetoxy-[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate, Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aR,6R,9S,11S,12S,12aS,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,4a,6,11-tetrahydroxy-8,12a,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR)-, hydrate (1:3), Benzenepropanoic acid,1-dimethylethoxy)carbonyl]amino]-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)
Drug Type Small molecule
Formula C₄₃H₅₃NO₁₄
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
InChI 1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKey ZDZOTLJHXYCWBA-VCVYQWHSSA-N
CAS Number 114977-28-5
ChEMBL ID CHEMBL92
ChEBI ID CHEBI:4672
TTD ID D0O5WP
Drug Bank ID DB01248
KEGG ID C11231
Toxicity Organism Test Type Route(Dose)
rat LD50 intraperitoneal(165 mg/kg)
mouse LD50 intraperitoneal(254 mg/kg)
rat LD50 oral(322 mg/kg)
Structure 2D-img
Download
2D MOL 3D MOL
03. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 265
Ref_2
Pair Name Wilforlide A, Docetaxel
Partner Name Wilforlide A
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Gene Regulation Down-regulation Expression ABCB1 hsa5243
Down-regulation Expression CDKN1A hsa1026
In Vitro Model PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
DU145 Prostate carcinoma Homo sapiens (Human) CVCL_0105
In Vivo Model These PC3-TxR cells were suspended in a 1:1 mixture of Matrigel and RPMI 1640 and subcutaneously implanted into planks of mice via injection.
Result Wilforlide A was found to enhance the chemosensitizing effect of docetaxel both in vitro and in vivo. Further studies are warranted to verify wilforlide A as a new drug candidate to overcome docetaxel resistance in prostate cancer.
Combination Pair ID: 244
Ref_3
Pair Name Saikosaponin A, Docetaxel
Partner Name Saikosaponin A
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Down-regulation Expression AKT1 hsa207
Down-regulation Expression MAP1LC3A hsa84557
Up-regulation Expression MAP1LC3B hsa81631
Down-regulation Expression SQSTM1 hsa8878
In Vitro Model LNCaP Prostate carcinoma Homo sapiens (Human) CVCL_0395
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
DU145 Prostate carcinoma Homo sapiens (Human) CVCL_0105
L-02 Papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_6926
HEK293T Healthy Homo sapiens (Human) CVCL_0063
WPMY-1 Healthy Homo sapiens (Human) CVCL_3814
In Vivo Model PC-3 cells (2×10⁶) were injected subcutaneously into the right flank of each mouse.
Result SSA is posed as a novel QCCs-eradicating agent by aggravating autophagy in QCCs. In combination with the current therapy, SSA has potential to improve treatment effectiveness and to prevent cancer recurrence.
Combination Pair ID: 377
Ref_4
Pair Name Resveratrol, Docetaxel
Partner Name Resveratrol
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Induction-->Necroptosis
Gene Regulation Up-regulation Phosphorylation ATM hsa472
Up-regulation Phosphorylation ATR hsa545
Up-regulation Phosphorylation H2AX hsa3014
In Vitro Model LNCaP Prostate carcinoma Homo sapiens (Human) CVCL_0395
Result We report resveratrol as an adjuvant drug candidate for improving the outcome of treatment in DTX therapy. Although the underlying mechanisms of necroptosis should be investigated comprehensively, targeting apoptosis and necroptosis simultaneously in the treatment of cancer can be a useful strategy for the development of promising drug candidates.
Combination Pair ID: 977
Ref_5
Pair Name Quercetin, Docetaxel
Partner Name Quercetin
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Induction-->Proliferation and apoptosis
In Vitro Model DU145 Prostate carcinoma Homo sapiens (Human) CVCL_0105
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
Result Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells
Combination Pair ID: 346
Ref_6
Pair Name Obovatol, Docetaxel
Partner Name Obovatol
Disease Info [ICD-11: 2B90] Colon cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression NFKB1 hsa4790
In Vitro Model LNCaP Prostate carcinoma Homo sapiens (Human) CVCL_0395
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
SW620 Colon adenocarcinoma Homo sapiens (Human) CVCL_0547
HCT 116 Colon carcinoma Homo sapiens (Human) CVCL_0291
Result These results indicate that obovatol augments cell growth inhibition by chemotherapeutics through inactivation of NF-kappaB and suggest that obovatol may have therapeutic advantages in the combination treatment with other chemotherapeutics.
Combination Pair ID: 252
Ref_7
Pair Name Nimbolide, Docetaxel
Partner Name Nimbolide
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Activity NFKB1 hsa4790
Down-regulation Expression XIAP hsa331
In Vitro Model LNCaP Prostate carcinoma Homo sapiens (Human) CVCL_0395
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
PC-3 D12 Prostate carcinoma Homo sapiens (Human) CVCL_4Y40
In Vivo Model 8-week-old male SCID mice were orthotopically implanted with LNCaP-Luc or PC-3-Luc cells to induce tumors.
Result The combination of NL and DTX significantly reduced the DNA binding ability of NF-κB in both cell types. NL significantly enhanced the antitumor effect of DTX and reduced metastases in orthotopic models of prostate cancer. NL abolishes DTX-induced-NF-κB activation to counteract cell proliferation, tumor growth, and metastasis in the prostate cancer models.
Combination Pair ID: 889
Ref_8
Pair Name Magnoflorine, Docetaxel
Partner Name Magnoflorine
Disease Info [ICD-11: 2B72] Gastric cancer Investigative
Biological Phenomena Induction-->Apoptosis
In Vitro Model 23132/87 Gastric adenocarcinoma Homo sapiens (Human) CVCL_1046
AGS Gastric adenocarcinoma Homo sapiens (Human) CVCL_0139
MKN74 Gastric tubular adenocarcinoma Homo sapiens (Human) CVCL_2791
NCI-N87 Gastric tubular adenocarcinoma Homo sapiens (Human) CVCL_1603
In Vivo Model Zebrafish embryos of the AB strain were studied under standard conditions (28.5 °C, 14 h light/10 h dark cycle) in an incubator.
Result Heterogeneous Cellular Response of Primary and Metastatic Human Gastric Adenocarcinoma Cell Lines to Magnoflorine and Its Additive Interaction with Docetaxel
Combination Pair ID: 854
Ref_9
Pair Name Kaempferol, Docetaxel
Partner Name Kaempferol
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Up-regulation Expression BECN1 hsa8678
Up-regulation Expression GABPA hsa2551
Down-regulation Expression MAP1LC3A hsa84557
Up-regulation Expression MAP1LC3B hsa81631
Up-regulation Expression SQSTM1 hsa8878
In Vitro Model DU145 Prostate carcinoma Homo sapiens (Human) CVCL_0105
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
In Vivo Model Mouse was subcutaneously inoculated with 5×10⁵ androgen-independent PC-3 human prostate cancer cells
Result The above cellular and animal data suggest that docetaxel in combination with kaempferol has significant anti-prostate cancer effects and that it works by inducing autophagy in cells.
Combination Pair ID: 930
Ref_10
Pair Name Gamma-Tocotrienol, Docetaxel
Partner Name Gamma-Tocotrienol
Disease Info [ICD-11: 2B66.Z] Oral cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression APAF1 hsa317
Down-regulation Expression BCL2 hsa596
Down-regulation Expression BIRC2 hsa329
Down-regulation Expression BIRC3 hsa330
Down-regulation Expression BIRC5 hsa332
Up-regulation Activity CASP3 hsa836
Up-regulation Activity CASP8 hsa841
Up-regulation Activity CASP9 hsa842
Up-regulation Expression CYCS hsa54205
Down-regulation Expression NFKB1 hsa4790
Up-regulation Cleavage PARP1 hsa142
Down-regulation Expression RELA hsa5970
Down-regulation Expression XIAP hsa331
In Vitro Model B88 Metastatic human oral cancer cell Homo sapiens (Human) N.A.
Result These findings suggest that the combination treatment with these agents may provide enhanced therapeutic response in oral cancer patients, while avoiding the toxicity associated with high-dose β-tubulin stabilization monotherapy.
Combination Pair ID: 493
Ref_11
Pair Name Gambogic Acid, Docetaxel
Partner Name Gambogic Acid
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Inhibition-->Cell metastasis
In Vitro Model 3LL Malignant tumors of the mouse pulmonary system Mus musculus (Mouse) CVCL_5653
In Vivo Model In an orthotopic mouse model of bone metastasis, the average survival of the DTX+GA combination group (32.61d±1.06 d) was significantly increased compared with that of the DTX group (25.75 d±0.67 d) or GA group (23.99 d±0.58 d), *P<0.01.
Result The combination of DTX and GA has synergistic effect and resulted in more effective inhibition of tumor metastasis, providing a strong preclinical rationale for the clinical development of the DTX+GA combination for treating bone metastasis of lung cancer.
Combination Pair ID: 592
Ref_12
Pair Name Delta-Tocotrienol, Docetaxel
Partner Name Delta-Tocotrienol
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Induction-->Necroptosis
Gene Regulation Up-regulation Cleavage CASP3 hsa836
Down-regulation Expression CFLAR hsa8837
Up-regulation Phosphorylation MLKL hsa197259
Up-regulation Phosphorylation RIPK1 hsa8737
Up-regulation Phosphorylation RIPK1 hsa8737
In Vitro Model DU145 Prostate carcinoma Homo sapiens (Human) CVCL_0105
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
Result The ability of δ-TT to induce necroptotic cell death may represent a promising therapeutical approach to overcome DTX chemoresistance in PCa.
Combination Pair ID: 404
Ref_13
Pair Name Curcumin, Docetaxel
Partner Name Curcumin
Disease Info [ICD-11: 2C31.Z] Head and neck squamous cell carcinoma Investigative
Biological Phenomena Induction-->Immunomodulatory
Gene Regulation Up-regulation Expression CD8A hsa925
Down-regulation Expression CXCL1 hsa2919
Up-regulation Expression IFNG hsa3458
Up-regulation Expression TNF hsa7124
Result Curcumin Enhances the Efficacy of Docetaxel by Promoting Anti-Tumor Immune Response in Head and Neck Squamous Cell Carcinoma
Combination Pair ID: 389
Ref_14
Pair Name Curcumin, Docetaxel
Partner Name Curcumin
Disease Info [ICD-11: 2B70] Esophageal cancer Investigative
Biological Phenomena Induction-->Apoptosis and autophagy
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP9 hsa842
Down-regulation Phosphorylation MTOR hsa2475
Down-regulation Phosphorylation PIK3CA hsa5290
In Vitro Model KYSE-150 Esophageal squamous cell carcinoma Homo sapiens (Human) CVCL_1348
KYSE-510 Esophageal squamous cell carcinoma Homo sapiens (Human) CVCL_1354
Result CUR combined with DTX induced apoptosis and autophagy of ESCC and probably worked through the PI3K/AKT/mTOR signaling pathway. The combination of the autophagy inhibitor, CUR and DTX may become a new treatment strategy for esophageal cancer.
Combination Pair ID: 161
Ref_15
Pair Name Celastrol, Docetaxel
Partner Name Celastrol
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Inhibition-->Cell metastasis
Gene Regulation Down-regulation Expression CBLL1 hsa79872
Up-regulation Expression CDH1 hsa999
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
MDA-MB-468 Breast adenocarcinoma Homo sapiens (Human) CVCL_0419
Result Our results showing anti-migratory/anti-invasive effects of celastrol and associated mechanisms provide new evidence for the development of celastrol as a potential anti-metastatic compound against highly aggressive breast cancer, and celastrol in combination with docetaxel might potentially be used as a novel regimen for the treatment of TNBC.
Combination Pair ID: 405
Ref_16
Pair Name Capsaicin, Docetaxel
Partner Name Capsaicin
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Gene Regulation Up-regulation Phosphorylation ACACA hsa31
Down-regulation Phosphorylation AKT1 hsa207
Down-regulation Phosphorylation MTOR hsa2475
Up-regulation Phosphorylation PRKAA1 hsa5562
Down-regulation Phosphorylation RPS6 hsa6194
Up-regulation Phosphorylation STK11 hsa6794
In Vitro Model PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
LNCaP Prostate carcinoma Homo sapiens (Human) CVCL_0395
In Vivo Model Prostate tumors were induced in athymic mice by subcutaneal injection of 5×10⁶ PC-3 cells or 5×10⁶ LNCaP cells, according to the experiment.
Result We showed that the synergistic anti-proliferative effect may be attributed to two independent effects: Inhibition of the PI3K/Akt/mTOR signaling pathway by one side, and AMPK activation by the other. In vivo experiments confirmed the synergistic effects of docetaxel and capsaicin in reducing the tumor growth of PC3 cells.
Combination Pair ID: 245
Ref_17
Pair Name Atractylenolide-III, Docetaxel
Partner Name Atractylenolide-III
Disease Info [ICD-11: 2B72] Gastric cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression FGFR1 hsa2260
Down-regulation Expression FGFR2 hsa2263
Down-regulation Expression FGFR4 hsa2264
In Vitro Model AGS Gastric adenocarcinoma Homo sapiens (Human) CVCL_0139
SGC-7901 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_0520
Result ATL and docetaxel treatment performed the synergistic effects on the inhibition of growth and induction of apoptosis in gastric cancer cells, and the underlying mechanism was mediated, at least partially, through the inhibition of FGFR1, -2, and -4.
Reversing Drug Resistance
Hide/Show
Combination Pair ID: 477
Ref_18
Pair Name Tricin, Docetaxel
Partner Name Tricin
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Inhibition-->Cell proliferation
Gene Regulation Down-regulation Expression MiR-21 KEGG ID N.A.
In Vitro Model PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
Result Tricin can be effective in the reduction of metastasis and drug resistance of Docetaxel.
Combination Pair ID: 60
Ref_19
Pair Name Quercetin, Docetaxel
Partner Name Quercetin
Disease Info [ICD-11: 2E02] Metastatic prostate cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression ABCB1 hsa5243
Down-regulation Phosphorylation AKT1 hsa207
Down-regulation Expression AR hsa367
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Expression PIK3CA hsa5290
In Vitro Model PC-3-R Prostate carcinoma Homo sapiens (Human) CVCL_C0QS
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
LNCaP Prostate carcinoma Homo sapiens (Human) CVCL_0395
In Vivo Model 5×10⁵ PC-3 cells were suspended in 100 μL PBS, or 2×108 LNCaP cells were suspended in 100 μL of matrigel, while PBS mixture (1:1) were injected subcutaneously into the right axillary fossa of mice.
Result Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
Combination Pair ID: 609
Ref_20
Pair Name Noscapine, Docetaxel
Partner Name Noscapine
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression ABCB1 hsa5243
Down-regulation Expression ABCC1 hsa4363
Down-regulation Expression BCL2 hsa596
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CASP3 hsa836
Down-regulation Expression CCND1 hsa595
Down-regulation Expression MMP2 hsa4313
Down-regulation Expression MMP2 hsa4313
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
In Vivo Model The orthotopic TNBC xenograft studies were carried out in female Balb/c Nude Mice. Following suitable acclimation of animals, 1.5 ×10⁶ wild-type and 1.0×10⁶ drug-resistant MDA-MB-231 TNBC cells were re-suspended in 100 µl of phosphate buffer solution (PBS), and implanted in the mammary fat pads using a 27-gauge needle Tumors were allowed to grow unperturbed for 10–14 days.
Result Chemo-sensitizing effect of Nos followed by DTX regime provide a promising chemotherapeutic strategy and its significant role for the treatment of drug-resistant TNBC.
Decreasing Drug Toxicity
Hide/Show
Combination Pair ID: 75
Ref_1
Pair Name Baicalein, Docetaxel
Partner Name Baicalein
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Inhibition-->Tumor angiogenesis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Down-regulation Expression CCNB1 hsa891
Down-regulation Expression CCND1 hsa595
Down-regulation Expression CDC25C hsa995
Down-regulation Expression CDK4 hsa1019
Down-regulation Expression CDK6 hsa1021
Down-regulation Expression CTNNB1 hsa1499
Up-regulation Phosphorylation GSK3B hsa2932
In Vitro Model A-549 Lung adenocarcinoma Homo sapiens (Human) CVCL_0023
Result Baicalein enhances the antitumor efficacy of docetaxel on nonsmall cell lung cancer in a β-catenin-dependent manner
04. Reference
No. Title Href
1 Baicalein enhances the antitumor efficacy of docetaxel on nonsmall cell lung cancer in a β-catenin-dependent manner. Phytother Res. 2020 Jan;34(1):104-117. doi: 10.1002/ptr.6501. Click
2 Chemosensitizing Effect and Efficacy of Wilforlide A in Combination With Docetaxel in Drug-resistant Prostate Cancer. In Vivo. 2022 Sep-Oct;36(5):2020-2031. doi: 10.21873/invivo.12928. Click
3 Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy. Cancer Lett. 2023 Feb 1;554:216011. doi: 10.1016/j.canlet.2022.216011. Click
4 Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells. Nutr Res Pract. 2021 Feb;15(1):12-25. doi: 10.4162/nrp.2021.15.1.12. Click
5 Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells. Cancers (Basel). 2023 Jan 31;15(3):902. doi: 10.3390/cancers15030902. Click
6 Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB. J Pharmacol Sci. 2009 Oct;111(2):124-36. doi: 10.1254/jphs.09048fp. Click
7 Nimbolide enhances the antitumor effect of docetaxel via abrogation of the NF-κB signaling pathway in prostate cancer preclinical models. Biochim Biophys Acta Mol Cell Res. 2022 Dec;1869(12):119344. doi: 10.1016/j.bbamcr.2022.119344. Click
8 Heterogeneous Cellular Response of Primary and Metastatic Human Gastric Adenocarcinoma Cell Lines to Magnoflorine and Its Additive Interaction with Docetaxel. Int J Mol Sci. 2023 Oct 24;24(21):15511. doi: 10.3390/ijms242115511. Click
9 Combination of Kaempferol and Docetaxel Induces Autophagy in Prostate Cancer Cells In Vitro and In Vivo. Int J Mol Sci. 2023 Sep 25;24(19):14519. doi: 10.3390/ijms241914519. Click
10 γ-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products. Int J Oncol. 2013;42(1):75-82. doi:10.3892/ijo.2012.1692 through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products. Int J Oncol. 2013;42(1):75-82. doi:10.3892/ijo.2012.1692 Click
11 Synergistic effect of docetaxel and gambogic acid on bone metastasis of lung cancer. Bull Cancer. 2023 May;110(5):478-486. doi: 10.1016/j.bulcan.2023.02.007. Click
12 Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells. Int J Mol Sci. 2023 Mar 3;24(5):4923. doi: 10.3390/ijms24054923. Click
13 Curcumin Enhances the Efficacy of Docetaxel by Promoting Anti-Tumor Immune Response in Head and Neck Squamous Cell Carcinoma. Cancer Invest. 2023 May;41(5):524-533. doi: 10.1080/07357907.2023.2194420. Click
14 Combination effect of curcumin with docetaxel on the PI3K/AKT/mTOR pathway to induce autophagy and apoptosis in esophageal squamous cell carcinoma. Am J Transl Res. 2021 Jan 15;13(1):57-72. Click
15 Celastrol inhibits the migration and invasion and enhances the anti-cancer effects of docetaxel in human triple-negative breast cancer cells. Med Oncol. 2022 Sep 7;39(12):189. doi: 10.1007/s12032-022-01792-y. Click
16 Combination of the natural product capsaicin and docetaxel synergistically kills human prostate cancer cells through the metabolic regulator AMP-activated kinase. Cancer Cell Int. 2019;19:54. Published 2019 Mar 8. doi:10.1186/s12935-019-0769-2. Click
17 Atractylenolide III Enhances the Anti-Neoplastic Efficacy of Docetaxel in Gastric Cancer Cell by Inhibiting Fibroblast Growth Factor Receptors 1, -2, and -4 Expression. J Environ Pathol Toxicol Oncol. 2019;38(3):217-227. doi: 10.1615/JEnvironPatholToxicolOncol.2019029196. Click
18 Tricin isolated from Allium atroviolaceum potentiated the effect of docetaxel on PC3 cell proliferation: role of miR-21. Nat Prod Res. 2019 Jun;33(12):1828-1831. doi: 10.1080/14786419.2018.1437439. Click
19 Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Int J Biol Sci. 2020 Feb 10;16(7):1121-1134. doi: 10.7150/ijbs.41686. Click
20 Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer. Sci Rep. 2017 Nov 20;7(1):15824. doi: 10.1038/s41598-017-15531-1. Click
It has been 46424 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP